论文部分内容阅读
目的分析尿激酶联合阿托伐他汀治疗急性心肌梗死的临床疗效及其对血清D-二聚体和超敏C反应蛋白(hs-CRP)水平的影响。方法选取2014年1月—2016年8月滁州市第一人民医院收治的急性心肌梗死患者90例,随机分为对照组和观察组,每组45例。在常规治疗基础上,对照组患者给予尿激酶治疗,观察组患者给予尿激酶联合阿托伐他汀治疗;两组患者均连续治疗8周。比较两组患者临床疗效、治疗前后血清D-二聚体和hs-CRP水平及治疗期间不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前两组患者血清D-二聚体和hs-CRP水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清D-二聚体和hs-CRP水平低于对照组(P<0.05);治疗后两组患者血清D-二聚体和hs-CRP水平均低于治疗前(P<0.05)。两组患者治疗期间均未出现药物相关不良反应。结论尿激酶联合阿托伐他汀治疗急性心肌梗死的临床疗效确切,可有效降低血清D-二聚体和hs-CRP水平,且安全性较高。
Objective To analyze the clinical efficacy of urokinase combined with atorvastatin in the treatment of acute myocardial infarction and its effect on serum levels of D-dimer and hs-CRP. Methods 90 patients with acute myocardial infarction who were admitted to Chuzhou First People’s Hospital from January 2014 to August 2016 were randomly divided into control group and observation group, with 45 cases in each group. On the basis of routine treatment, patients in the control group were treated with urokinase and patients in the observation group were treated with urokinase combined with atorvastatin. Patients in both groups were treated continuously for 8 weeks. The clinical efficacy, serum D-dimer and hs-CRP levels before and after treatment were compared between the two groups and the incidence of adverse reactions during treatment. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). There was no significant difference in serum D-dimer and hs-CRP level between the two groups before treatment (P> 0.05). After treatment, the levels of serum D-dimer and hs-CRP in the observation group were lower than those in the control group P <0.05). After treatment, serum D-dimer and hs-CRP levels in both groups were lower than before treatment (P <0.05). No drug-related adverse events occurred in both groups during treatment. Conclusions Urokinase combined with atorvastatin is effective in the treatment of acute myocardial infarction. It can effectively reduce the level of serum D-dimer and hs-CRP, and is safe.